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LETTER
RESEARCH LETTERThree years of methotrexate and
secukinumab: Outcomes of psoriatic
arthritis in a real-life settingTo the Editor: Only a small number of studies have
evaluated the efficacy and safety of secukinumab in
real-life settings in patients with psoriatic arthritis
(PsA),1,2 and to our knowledge there are no data on
the long-term efficacy of secukinumab in PsA in
real-world practice. We present data on the clinical
efficacy of secukinumab in PsA in 51 patients with
PsA in a real-life setting. Only patients receiving
treatment with methotrexate and secukinumab
300 mg were enrolled. Exclusion criteria were latent
tuberculosis, liver infections, low grade or in situ
malignancy diagnosed \5 years before the
screening visit, and pregnancy. After 156 weeks,
data were available on 43 patients receiving meth-
otrexate and secukinumab 300 mg for $156
consecutive weeks. Patients were evaluated
through measurement of systemic inflammation
(erythrocyte sedimentation rate and C-reactive pro-
tein), clinical severity scores (Disease Activity Score
over 28 joints [DAS28], Psoriasis Area Severity Index
[PASI], body surface area [BSA], number of swollen
and tender joints), and patient self-assessment
questionnaires (Dermatology Life Quality Index
[DLQI] and Multidimensional Assessment of
Fatigue [MAF]) after 52, 104, and 156 weeks.
Twenty-four of 43 (55.8%) patients had previously
failed biologic therapy (mean age 58 years, mean
disease duration 12.2 years). Nineteen patients
(44.2%) were na€ıve for a biologic agent (mean age
62 years, mean disease duration 9.2 years).
Outcomes in the biologic treatmentena€ıve group
over 156 weeks are shown in Table I. At baseline, the
mean number of swollen and tender joints was
2.8 6 1.7 and 9.1 6 4.0, respectively. There were
no swollen or tender joints over 156 weeks. The









mean 6 SD m
0 2.8 6 1.7 9.1 6 4.0 25.6 6 13.3 8.6 6 5.28
52 0.0 6 0.0 0.0 6 0.0 14.4 6 6.9 3.0 6 1.4
104 0.0 6 0.0 0.0 6 0.0 15.8 6 9.0 1.3 6 0.4
156 0.0 6 0.0 0.0 6 0.0 10.6 6 4.7 0.5 6 0.3
BSA, Body surface area; CRP, C-reactive protein; DAS28, Disease Activity
erythrocyte sedimentation rate; MAF, Multidimensional Assessment of F
J AM ACAD DERMATOLfollow-up visits versus baseline. C-reactive protein
appeared to decrease progressively over the 3-year
period, while DAS28, PASI, and BSA remained low
over 156 weeks. Substantial improvement in quality
of life indices wasmaintained over 3 years. For DLQI,
scores were consistently around 1, indicating that
quality of life is not affected by the disease.
Outcomes in patients with a previous failure of a
biologic agent over 156 weeks are shown in Table II.
In this group, no swollen joints were observed at any
follow-up visit, although a low number of tender
joints was seen over 3 years. Values of erythrocyte
sedimentation rate decreased substantially from
baseline and remained stable over 3 years, similar
to what was observed for C-reactive protein. DAS28,
PASI, and BSA also remained stable and low over the
follow-up period. Quality of life measures were
decreased and remained low over 3 years. For the
DLQI, scores were consistently\1.
There were no significant differences between the
biologic treatmentena€ıve and previous failure of a
biologic agent groups over 3 years for swollen joints,
tender joints, DAS28, PASI, BSA, DLQI, or MAF. No
severe adverse events were observed. Therefore, for
all endpoints evaluated, good effectiveness of secu-
kinumab was observed at 52 weeks and maintained
for #156 weeks of treatment, which was indepen-
dent of the severity of disease and previous treat-
ments. Our results add to the evidence base that the
efficacy of secukinumab is maintained for #3 years
in a real-life setting in patients with PsA, confirming
the good results observed during 5 years in the
FUTURE 1 trial.3
This study was conducted in accordance with the
ethical principles of the Declaration of Helsinki and
received approval by the Comitato Etico Interaziendale
A.O.U. Citta della Salute e della Scienza di Torino, A.O.
Ordine Mauriziano, A.S.L. Citta di Torino (approval num-











5.1 6 1.3 8.2 6 5.4 9.6 6 6.8 12.3 6 7.0 3.0 6 1.3
2.2 6 0.4 1.0 6 0.4 3.6 6 1.2 1.1 6 0.4 2.7 6 1.4
2.1 6 0.5 0.9 6 0.3 2.6 6 1.9 1.0 6 0.4 2.6 6 1.2
2.2 6 0.5 1.0 6 0.3 2.4 6 1.4 1.1 6 0.4 1.8 6 1.1
Score over 28 joints; DLQI, Dermatology Life Quality Index; ESR,
atigue; PASI, Psoriasis Area Severity Index; SD, standard deviation.
n 2021 1




















0 6.0 6 4.9 12.2 6 8.0 37.4 6 22.2 14.9 6 10.1 5.7 6 1.3 10.1 6 7.1 20.8 6 10.1 17.3 6 8.9 22.5 6 11.0
52 0.0 6 0.0 0.3 6 0.1 22.4 6 14.6 2.2 6 1.3 2.4 6 0.6 1.3 6 0.8 1.4 6 0.3 0.8 6 0.6 2.9 6 1.6
104 0.0 6 0.0 0.2 6 0.1 18.7 6 9.1 1.1 6 0.2 2.4 6 0.5 1.1 6 0.4 1.2 6 0.1 0.7 6 0.5 2.8 6 1.6
156 0.0 6 0.0 0.2 6 0.1 16.1 6 6.8 1.0 6 0.3 2.4 6 0.6 1.3 6 0.8 1.8 6 0.3 0.8 6 0.5 2.1 6 1.6
BSA, Body surface area; CRP, C-reactive protein; DAS28, Disease Activity Score over 28 joints; DLQI, Dermatology Life Quality Index; ESR,
erythrocyte sedimentation rate; MAF, Multidimensional Assessment of Fatigue; PASI, Psoriasis Area Severity Index; SD, standard deviation.
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